Search results
Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use
Zacks via Yahoo Finance· 5 months agoFDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage...
Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
Benzinga via Yahoo Finance· 2 months agoOn Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8...
Merck (MRK) Gets FDA Nod for Keytruda Expansion in Gastric Cancer
Zacks via Yahoo Finance· 7 months agoFollowing this approval, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers....
Can The No. 1 Pharma Stock, Merck, Continue Its Blazing Run In 2023?
Investor's Business Daily· 1 year agoIn the span of a month in late 2022, Merck gained a new chairman, announced a $1.35 billion takeover...
Merck's (MRK) Keytruda for Liver Cancer to Undergo FDA Review
Zacks via Yahoo Finance· 1 year agoFDA accepts Merck's (MRK) supplemental biologics license application for Keytruda plus chemotherapy...
Merck Scores Major Drug Approval, Easing Pain From Keytruda Patent Expiration
Barrons.com· 3 months agoMerck secured Food and Drug Administration approval for a drug widely expected to be an era-defining...
Drugmakers go under the skin, skirting early US Medicare price negotiations
Reuters via Yahoo Finance· 11 months agoInjectable versions of some widely-used cancer drugs including Johnson & Johnson's blockbuster...
Moderna just used a personalized vaccine to treat cancer, and it could signal a major breakthrough...
Business Insider via Yahoo News· 2 years agoStéphane Bancel, the CEO of Moderna.Nancy Lane/MediaNews Group/Boston Herald Moderna's cancer...
Merck Stock Has Been A Laggard For Seven Months. Is It Staging A Comeback?
Investor's Business Daily· 5 months agoMerck stock is shrugging off seven months of underperformance, shooting more than 7% higher in the...
Merck's Rumored $40 Billion Seagen Takeover Hits A Snag On Price
Investor's Business Daily· 2 years agoMerck's rumored takeover of cancer-focused biotech Seagen has stalled on price, according to a...